Clinical and Surgical Management of Zollinger-Ellison Syndrome: A Literature Review

Article Sidebar

PDF
Published: Dec 14, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i12-27
Keywords:
.

Main Article Content

Melissa Anahí Chan Verdugo
Universidad Autónoma de Sinaloa, Facultad de medicina. Sinaloa, México.
Rossy Mariel Rebollar Soto
Universidad Latinoamericana. México.
Diana Laura Noverón Salgado
Universidad Latinoamericana. México.
María Erika Boza Medrano
Universidad Juárez del Estado de Durango. Durango, México.
William Arteaga León
Benemérita Universidad Autónoma de Zacatecas. Zacatecas, Zacatecas, México.

Abstract

Zollinger-Ellison Syndrome is a rare disease caused by tumors called "Gastrinomas", causing high levels of gastrin that produces acid hypersecretion and even gastric ulcers. We present a 20-year-old patient with a 2-month history of pain in the epigastrium accompanied by nausea, vomiting, and weight loss with a history of upper gastrointestinal bleeding from a duodenal ulcer, which on physical examination revealed a tumor in the epigastrium. Contrast-enhanced abdominal CT showed a tumor mass in the tail of the pancreas. She underwent surgery, performing a corporocaudal pancreatectomy and splenectomy, with favorable post-surgical evolution. The anatomopathological study reports pancreatic gastrinoma.

Article Details

How to Cite
Chan Verdugo, M. A. ., Rebollar Soto, R. M., Noverón Salgado, D. L. ., Boza Medrano, M. E. ., & Arteaga León, W. . (2022). Clinical and Surgical Management of Zollinger-Ellison Syndrome: A Literature Review. International Journal of Medical Science and Clinical Research Studies, 2(12), 1508–1511. https://doi.org/10.47191/ijmscrs/v2-i12-27
Issue
Vol. 2 No. 12 (2022): Volume 02 Issue 12 December 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumor of the pancreas. Ann Surg. 1955; 142:709-23.

II. Kent RB, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981; 193:185-90.

III. Stabile BE, Morrow DJ, Passaro E. The gastrinoma triangle: Operative implications. Am J Surg. 1984; 147:25-31.

IV. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Possibly primary lymph node gastrinoma: Occurrence, natural history, and predictive factors. Ann Surg. 2003; 237:650-9.

V. Klöppel G, Clemens A. The biological relevance of gastric neuroendocrine tumors. Yale J Biol Med. 1996; 69:69-74.

VI. Hirschowitz BI. Pathobiology and management of hypergastrinemia and the Zollinger-Ellison syndrome. Yale J Biol Med. 1992; 65:659-76.

VII. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors. Gastroenterology. 2008; 135:1469-92.

VIII. Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: Recent insights and advances. Curr Gastroenterol Rep. 2009; 11:433-41.

IX. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(Suppl.):1807-43.

X. Bordi C, D’Adda T, Azzoni C, Ferraro G. Pathogenesis of ECL tumors in humans. Yale J Biol Med. 1998; 71:273-84.

XI. Waldum HL, Brenna E, Sandvik AK. Relationship of ECL cells and gastric neoplasia. Yale J Biol Med. 1998; 71:325-35

XII. Burkitt MD, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2009; 15:1-16.

XIII. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA, Norton JA. Lethality of multiple endocrine neoplasia type 1. World J Surg. 1998; 22:581-7.

XIV. Veldhuis JD, Norton JA, Wells SA, Vinik AI, Perry RR. Surgical versus medical management of multiple endocrine neoplasia (MEN) type 1. J Clin Endocrinol Metab. 1997; 82:357-64.

XV. Lopez CL, Waldmann J, Fendrich V, Langer P, Kann PH, Bartsch DK. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN. Langenbecks Arch Surg. 2011; 396:1187-96.

XVI. Jkerström G, Stjlberg P, Hellman P. Surgical management of pancreatic-duodenal tumors in multiple endocrine neoplasia syndrome type 1. Clinics. 2012; 67:173-8.

XVII. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome – Current concepts in diagnosis and management. N Engl J Med. 1987; 317:1200-9.

XVIII. Feldman M, Schiller LR, Walsh JH, Fordtran JS, Richardson CT. Positive intravenous secretin test in patients with achlorhydria-related hypergastrinemia. Gastroenterology. 1987;93: 59-62.

XIX. Andersen DK. Current diagnosis and management of ZollingerEllison syndrome. Ann Surg. 1989; 210:685-703.

XX. Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult. World J Gastroenterol. 2012; 18:5495-503

XXI. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger-Ellison syndrome and mismeasurements of gastrin. Gastroenterology. 2011; 140:1444-53.

XXII. Vinic, A. & Raymond, E. (2013). Pancreatic Neuroendocrine Tumors: Approach to Treatment with Focus on Sunitinib. Therapeutic Advances in Gastroenterology, 6 (5), 396–411.

XXIII. Tiensuu, E., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., et al. (2014). Nordic Guidelines (2014). for Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms. Acta Oncológica, 53 (10), 1284- 1297.

XXIV. Fendrich,V. (2012). Surgical Treatment of Zollinger - Ellison Syndrome. Pancreatic Disorders & Therapy, 2 (1), 1-2

XXV. Tomassetti, P., Campana, D., Pisciteli, L., Mazzotta, E., Brocchi, E., Pezzilli, R., et al. (2005). Treatment of Zollinger – Ellison Syndrome. World Journal of Gastroenterology, 11(35), 5423- 5432.

XXVI. Metz, D. (2012). Diagnosis of the Zollinger – Ellison Syndrome. Clinical Gastroenterology and Hepatology, 10, 126-130.

Most read articles by the same author(s)